FIN 588 | Session 5 | Roche's Acquisition of Genentech
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
FIN 588 | Session 5 | Roche's Acquisition of Genentech
-
Lu par :
-
De :
À propos de ce contenu audio
FIN 588 | Session 5 | Roche's Acquisition of Genentech - 2026
In 2008, the Swiss pharmaceutical giant Roche proposed acquiring the remaining 44% of its fiercely independent biotech subsidiary, Genentech, offering $89 per share in a deal valued at approximately $100 billion.
This strategic move was designed to reduce operational overlap, secure unfettered access to Genentech's substantial free cash flow, and protect Roche's access to an innovative drug pipeline before a key licensing agreement expired in 2015.
However, the acquisition faced a significant valuation impasse when Genentech's special committee rejected the offer as inadequate, countered with a price of $112 to $115 per share, and refused to negotiate downward despite the burgeoning 2008 global financial crisis.
Roche's leadership, including Franz Humer and Severin Schwan, had to navigate the extreme difficulty of securing $44 billion in debt financing during a worldwide credit freeze while fearing that a hostile tender offer might alienate the star scientists and managers central to Genentech's success.
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
